Skip to content
Active, not recruitingN/A

Trifecta Research Study

NCT07717866 · Axial Therapeutic Research

Closed to entry
Status
Not accepting participants
Not applicable
Phase
52
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder (PTSD) and traumatic brain injury-related cognitive symptoms among Special Operations Forces (SOF) combat veterans.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • PTSD Checklist for Diagnostic and Statistical Manual (DSM)-5 (PCL-5)

    Measured over Up to 12 months follow up

  • Medical Outcomes Study Cognitive Functioning Scale (MOS-CF)

    Measured over Up to 12 months follow up

  • Stroop Squared Task

    Measured over Up to 12 months follow-up

  • Externalized Free Recall with Emotional Words Task

    Measured over Up to 15 weeks (Post-MeRT for Group A, Post-IM/5MeO for Group B)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * At least 18 years of age * Sponsored by SOC-F Program Exclusion Criteria (evaluated by SOC-F, not Axial Therapeutic Research): * Diagnosis of Schizophrenia, Bipolar I or II disorder for which patient has been hospitalized or medicated, Depersonalization and/or Derealization Disorder * Cerebellar dysfunction, Epilepsy, Psychosis or acute confusional state, Dementia * Prolonged corrected QT interval (QTc) Interval (450ms in males; 470ms in females) * History of heart failure or hypertrophic heart * Active blood clots (e.g., Pulmonary embolism, Deep vein thrombosis) * Major respiratory conditions (e.g., Emphysema, Cystic fibrosis) * Severe chronic gastrointestinal issues (e.g., bleeding ulcer, leaky gut syndrome) * Within 6 months of surgeries * Abnormal blood test results (e.g., potassium or magnesium outside normal range) * Impaired kidney or liver function * Refusal to taper off of selective serotonin reuptake inhibitor (SSRI) medication

Where

1 study site

FacilityCityRegionCountry
Axial Therapeutic ResearchNorthridgeCaliforniaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07717866 on ClinicalTrials.gov →

Last updated in the registry 2026-07-21. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits